|
Why Does BioNTech Have to Pay the NIH Royalties for Licensing mRNA Bioweapon Technology, but Pfizer Doesn't?
Because every COVID-19 mRNA bioweapon vaccine manufacturer entered into a royalty agreement with the NIH to pay royalties on their numerous mRNA vaccine bioweapon technology patents….except for Pfizer
December 29, 2024: Over the past 3 years, there have been multi-billion dollar battles over the royalty payments for the COVID-19 mRNA nanotechnology patents, patents such as this NIH patent for vaccine naonotechnology for use as a bioweapon….
There are thirty-two (32) mRNA technology and mRNA-related patents applicable across the 157 industrial countries (PCT) including the United States, China, India and European countries.
Last year, Moderna paid the NIH $400 million for use of just ONE (1) of their patents, and then the NIH pushed Moderna to sue Pfizer (on their behalf).
Example NIH mRNA ‘Vaccine’ Royalty Agreement
The only reason why companies, governments, and individuals file patents is because they expect to get a payout some day. And in the case of the COVID-19 mRNA nanotechnology patents, the payouts should be HUGE. The example royalty rate in the NIH mRNA Vaccine agreement is 8% on NET sales.
As Pfizer generated approximately $87 billion in revenue from 2021-2023 COMIRNATY (COVID-19 mRNA ‘vaccine’) sales, per the example NIH royalty agreement (and assuming a 25% cost of goods sold), Pfizer would owe the NIH more than $5 billion in royalty payments, but they don’t. Why?
Because every COVID-19 mRNA bioweapon vaccine manufacturer entered into a royalty agreement with the NIH to pay royalties on their numerous mRNA vaccine bioweapon technology patents….except for Pfizer. ...
Keep reading with a 7-day free trial
Subscribe to The Kingston Report to keep reading this post and get 7 days of free access to the full post archives.
A subscription gets you:
Subscriber-only posts with references | |
Post comments and join the community | |
Access to ALL articles beginning in 2022. Without a paid subscription articles are not available after 3 weeks. |
No comments:
Post a Comment